Background: α-Pyrrolidinopentiophenone (α-PVP) has been reported to be rewarding in a variety of pre-clinical models. Given that a number of drugs of abuse have both rewarding and aversive effects, the balance of which influences addiction potential, the present study examined the aversive properties of α-PVP by assessing its ability to induce taste avoidance. This assessment was made in a combined taste avoidance/place conditioning design that also allowed an evaluation of the relationship between α-PVP's aversive and rewarding effects. Methods: Male Sprague-Dawley rats were exposed to a novel saccharin solution, injected with one of four doses of α-PVP (0, 0.3, 1.0 and 3.0 mg/kg) (IP) and placed on one side of a place conditioning apparatus. The next day, they were injected with vehicle, given access to water and placed on the other side. Following four conditioning cycles, saccharin avoidance and place preferences were then assessed. The effects of α-PVP on body temperature were also examined. Results: α-PVP induced dose-dependent taste avoidance as well as significant increases in time spent on the drugpaired side (although this effect was not dependent on dose). α-PVP also induced dose-and time-dependent hyperthermia. Conclusions: α-PVP induced significant taste avoidance whose strength relative to the psychostimulants methylenedioxypyrovalerone (MDPV) and cocaine paralleled their relative binding to the dopamine transporter. Similar to other drugs of abuse, α-PVP has both aversive and rewarding effects. It will be important to assess how various experiential and subject variables impact these effects and their balance to predict abuse liability.
Introduction
Drugs of abuse have both rewarding and aversive effects (Cunningham, 1979; Turenne et al., 1996; Verendeev and Riley, 2011) , and it is the balance of these two affective properties that impact their use and abuse (Colechio et al., 2014; Riley et al., 2009; Stolerman, 1985; Wise et al., 1976) . One class of drugs only beginning to be examined in this context are the synthetic cathinones (Al-Juhaishi et al., 2012; Busardò et al., 2015; Kalix, 1992; Patel, 2000) . Among these newly emerged compounds is α-pyrrolidinopentiophenone (α-PVP; aka "gravel"; "flakka" or "five dollar insanity"), one of the most popular "second-generation bath salts" (Marinetti and Antonides, 2013; Marusich et al., 2014) . α-PVP, despite being known as a 'secondgeneration' bath salt, is actually the structural parent of the 'first generation' bath salt MDPV and has many characteristics in common (Aarde et al., 2015; Glennon and Young, 2016; Katselou et al., 2015; Marusich et al., 2014) . Although α-PVP has not received the same attention as MDPV (for reviews on the behavioral and biochemical actions of MDPV, see Baumann et al., 2013; Glennon and Young, 2016; King and Riley, 2016; Meltzer et al., 2006; Simmler et al., 2013) , some characterization has recently begun. For example, Aarde et al. (2015) reported that in rats α-PVP was similar to MDPV in both potency and efficacy in supporting intravenous self-administration (see also Schindler et al., 2015) . Additionally, Watterson et al. (2014) demonstrated that in rats α-PVP dose-dependently decreased ICSS thresholds in a discrete trials current threshold procedure (Marusich et al., 2016) . Consistent with this, Gatch et al. (2015) reported that in mice α-PVP induced significant dose-dependent conditioned place preferences.
As noted above, most drugs of abuse have both rewarding and aversive effects and their balance impacts abuse potential. Although α-PVP's rewarding effects have been examined, little is known of its aversive effects. Previous work has reported that a variety of CNS stimulants (including MDPV; see King et al., 2014 King et al., , 2015 Merluzzi et al., 2013) are effective in inducing dose-dependent conditioned taste avoidance (CTA), a behavioral index of the aversive effects of drugs (Garcia and Ervin, 1968; Lin et al., 2016; Riley and Tuck, 1985) . The taste avoidance procedure is one in which animals are given access to a novel taste and then injected with a drug. As a consequence of this pairing, consumption of the drug-paired taste is suppressed, a suppression generally described to be function of the drug's aversive effects (Garcia and Ervin, 1968; Revusky and Garcia, 1970; Riley and Tuck, 1985; Rozin and Kalat, 1971 ; for a review on the history of CTA, see Freeman and Riley, 2009 ). The present study began the initial characterization of the aversive effects of α-PVP by examining its ability to induce taste avoidance.
Although many drugs have been reported to induce taste avoidance, the mechanism underlying such effects in general remains unknown (Gamzu et al., 1985; Hunt and Amit, 1987 ; for reviews, see Lin et al., 2016; Verendeev and Riley, 2012) . The limited work with cocaine suggests that dopamine activity may mediate, in part, its aversive effects. For example, a variety of dopamine antagonists block cocaineinduced taste avoidance (Freeman et al., 2005b; Hunt et al., 1985; Serafine et al., 2011 Serafine et al., , 2012 ) and cocaine's aversive effects are significantly attenuated by a prior history with other dopamine-reuptake inhibitors, an effect generally interpreted to be a function of crosstolerance between the compounds (Berman and Cannon, 1974; Freeman et al., 2005b; LeBlanc and Cappell, 1974; Serafine and Riley, 2010 ; for a review, see Riley and Simpson, 2001) . It is interesting in this context that MDPV appears to be roughly 10 times more potent than cocaine in inducing taste avoidance (Freeman et al., 2005a, b; King et al., 2014 King et al., , 2015 Marusich et al., 2014; Merluzzi et al., 2013; Serafine et al., 2012; Woloshchuk et al., 2016) . The relative potencies of MDPV and cocaine in inducing taste avoidance parallel their relative efficacy at blocking DA reuptake (MDPV: IC50 values of 4.1 ± 0.5 nM; cocaine: IC50 values of 211 ± 19 nM). Although α-PVP also inhibits the reuptake of dopamine, its relative efficacy is much more similar to MDPV than cocaine (α-PVP: IC50 values of 12.8 ± 1.2 nM; Marusich et al., 2014) . If dopamine activity mediates the aversive effects of α-PVP in a manner similar to that for cocaine (and MDPV; see Woloshchuk et al., 2016) , it might be expected to induce taste avoidance to a degree comparable to MDPV and at doses less than those needed to induce avoidance with cocaine and doing so with fewer conditioning trials.
As noted above, Gatch et al. (2015) have previously reported CPP with α-PVP in mice; however, species differences in place preference conditioning have been noted with other drugs (see Chaperon et al., 1998; Cunningham et al., 1993; Hempel et al., 2016; Hutcheson et al., 1998; Sañudo-Peña et al., 1997; Valjent and Maldonado, 2000) . Accordingly, place preference conditioning was also assessed in the present experiment. Specifically, rats were allowed access to a novel saccharin solution and injected with one of four doses of α-PVP (0, 0.3, 1.0 and 3.0 mg/kg) prior to being placed in a distinct environment, a procedure used by our laboratory (Hempel et al., 2016; King et al., 2015; Pomfrey et al., 2015; Simpson and Riley, 2005; Verendeev and Riley, 2011) and others (Brockwell et al., 1991; Sherman et al., 1980; Wang et al., 2010) to simultaneously assess the aversive (CTA) and rewarding (CPP) effects of a host of drugs of abuse.
Core body temperature was also examined in response to α-PVP. Increases in body temperature is commonly observed with a number of psychostimulants (for MDMA, see Dafters and Lynch, 1998 ; for methamphetamine, see Fukumura et al., 1998 ; for cocaine, see Cappon et al., 1998 ; for MDPV, see Fantegrossi et al., 2013; King et al., 2014; Kiyatkin et al., 2015; Merluzzi et al., 2013) . Interestingly, Aarde et al. (2015) have recently reported hypothermia in rats receiving 5.6 and 10.0 mg/kg of either α-PVP or MDPV. To extend these assessments of temperature changes with α-PVP, following the abovementioned behavioral tests, subjects were injected with α-PVP and core body temperature was examined. This assessment also allowed for an initial examination of the relationship of taste avoidance conditioning to changes in temperature (see Cunningham et al., 1992; Merluzzi et al., 2013) .
General methods

Subjects
The subjects were 33 experimentally naïve male Sprague-Dawley rats (Envigo, Indianapolis, IN). Rats entered the animal research facility at American University on postnatal day (PND) 23 and were allowed to mature undisturbed with the exception of weekly weight assessments from PND 23 though PND 83. Beginning on PND 83, animals were weighed daily to index health status and to reduce handling stress during the experimental procedures. Subjects were 90 days old and weighed between 321 and 445 g at the beginning of the study. All procedures adhered to the Guidelines for the Care and Use of Laboratory Animals (National Research Council, 2011 ) and the Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research Council, 2003) and were approved by the Institutional Animal Care and Use Committee at American University.
Drugs and solutions
Racemic α-pyrrolidinopentiophenone HBr (α-PVP) (synthesized at the Drug Design and Synthesis Section, NIDA) was dissolved in isotonic saline (0.9%) and injected intraperitoneally (IP) at 0.3, 1.0 and 3.0 mg/ kg. Concentration was held constant across dose groups (1 mg/ml), and animals were injected at a volume of 1 ml/kg. Isotonic saline (vehicle) was administered to controls at the same volume. Each drug (and vehicle) solution was prepared daily and was passed through a 0.2 um filter prior to injection. Saccharin (sodium saccharin, Sigma) was prepared as a 1 g/l (0.1%) solution in tap water.
Apparatus
Subjects were housed two per home-cage in OptiRat Plus cages (38.9 × 56.9 × 26.2 cm; 1181 cm 2 ). The room in which the cages were located was maintained on a 12-h light/dark cycle (0800-2000 h) at 23°C. Unless stated otherwise, food and water were available ad libitum. During habituation, training and testing (see below), animals were transferred to individual hanging, stainless-steel wire mesh test cages (24.3 × 19 × 18 cm) on the front of which graduated Nalgene tubes could be placed for fluid presentation. Eight identical threechambered conditioned place preference systems (San Diego Instruments Place Preference System, San Diego, CA) were employed for place preference conditioning (for a detailed description, see Hempel et al., 2016) . During training and testing, the procedure room was lit with an 85-watt red light mounted in the ceiling.
Procedure
Habituation
On PND 90, subjects were deprived of water for 24 h and on the following day were given 20-min access to tap water in the test cages. Following this, the animals were returned to their home cages. This procedure was repeated for 10 days to allow water consumption to stabilize (drinking within 2 s with the average volume of water consumed not increasing or decreasing by > 2 ml for 3 consecutive days). Fluid was presented in graduated 50-ml Nalgene tubes, and intake was indexed by the difference between pre-and post-consumption volumes.
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Pre-test
Following stable water consumption (PND 101), subjects were given 20-min access to water in the test cages, placed into the conditioned place preference (CPP) apparatus for 15 min and allowed to investigate all three chambers freely. Subjects spent an average of 216.2 s on the white side and 398.6 s on the black side of the apparatus. Time spent in the two main chambers was significantly different (p < 0.05), indicating that the apparatus was biased with rats preferring the black side over the white. Accordingly, a biased training procedure was employed such that subjects were assigned to receive drug injections on the nonpreferred side of the apparatus (Le Foll and Goldberg, 2004; Tzschentke, 1998) . Following access to the place preference chambers, animals were returned to their home cages. Chambers were wiped down with a soapy alconox and water solution between animals.
Combined conditioned taste avoidance/conditioned place preference
On Day 1 of this phase (PND 102), rats were placed in their test cages and allowed 20-min access to a novel saccharin solution. Subjects were matched on saccharin consumption, assigned to four groups such that consumption was comparable and injected (IP) with either 0 (saline vehicle), 0.3, 1.0 or 3.0 mg/kg α-PVP (n = 8-9 per group). This dose range was based on work by Watterson et al. (2014) in which 0.1, 0.3, 1.0, 3.0 and 5.0 mg/kg α-PVP were assessed in a discrete trials current intensity threshold ICSS procedure that resulted in significant ICSS threshold reductions at 0.3 and 1.0 mg/kg. There were no significant effects at 0.1 mg/kg and at 3.0 mg/kg (see also Aarde et al., 2015; Marusich et al., 2014) , and the highest dose (5.0 mg/kg) induced significant elevations in ICSS thresholds. Given that we were attempting to characterize α-PVP's aversive effects, we began with doses within the range that was behaviorally effective as reported by Watterson et al. Following the injections, they were taken to an adjacent room and placed on the non-preferred side of the CPP apparatus (based on the pretest data for each rat) for 30 min. Subjects were then returned to their home cages. On the next day (Day 2), rats were given 20-min access to water in the test cages, injected with vehicle and placed on their initially preferred side for 30 min. This twoday cycle was repeated for a total of four times. On Day 9, animals were given 20-min access to tap water and placed in the center gray middle area of the CPP apparatus and given 15 min to explore the apparatus freely. Time spent in each area was recorded and evaluated for any changes in side preference relative to the amount of time spent in the chambers on the Pre-test. The next day, animals were placed in the test cages and given 20-min access to both saccharin and tap water in a final two-bottle avoidance test with no subsequent injections. Consumption of both saccharin and water was recorded after 20 min had elapsed. Animals were returned to their home cages with ad libitum water access.
Temperature assessment
Following a 3 week wash-out period (PND 134), temperature probes (Bio Medic Data Systems, Seaford, DE; Model #IPTT-300) were implanted in each animal. Rats were allowed to recover undisturbed for 1 day, and on PND 136-138 they were weighed and the temperature transponders were scanned to check for proper function. On PND 139 and 140, all subjects were scanned for temperature, weighed and injected with saline (IP). On PND 141, they were handled the same as on PND 139 and 140 except that additional temperature scans were taken 30-, 60-, 120-and 180-min post injection. The procedure on PND 142 was identical except subjects were randomly injected (IP) with either 0 (vehicle), 0.3, 1.0 and 3.0 mg/kg α-PVP. For each temperature recording, the probe was scanned three times and the three measurements averaged.
Statistical analyses 2.5.1. Conditioned taste avoidance
Saccharin consumption on conditioning trials was analyzed using a 4 × 4 mixed model ANOVA with the between-subjects factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and the within-subjects factor of Trial (1-4). In the instance of a significant 2-way interaction, simple effects of Dose at each Trial (multivariate analyses) and Trial at each Dose (multivariate analyses) were assessed. Water consumption on recovery days was similarly analyzed using a 4 × 4 mixed model ANOVA with the between-subjects factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and the within-subjects factor of Recovery Day (1-4). In the instance of a significant 2-way interaction, simple effects of Dose at each Recovery Day (multivariate analyses) and Recovery Day at each Dose (multivariate analyses) were assessed.
Percent saccharin of total fluid consumption on the final two-bottle test was analyzed using a one-way ANOVA with the between-subject factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and Bonferroniadjusted multiple comparisons. Saccharin preference was calculated as a percentage, whereby volume of saccharin consumed was divided by total volume consumed (water + saccharin). Total fluid volume consumed (water + saccharin) on the final two-bottle test was also examined using a one-way ANOVA with the between-subject factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and Bonferroni-adjusted multiple comparisons.
Conditioned place preference
Time spent on the drug-paired side (DPS) was analyzed using a 4 × 2 mixed model ANOVA with the between-subject factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and the within-subject factor of Test (Pre-test and Post-test), followed by Bonferroni-corrected multiple comparisons as warranted.
Temperature assessment
Core body temperature (C) was analyzed using a 4 × 5 mixed model ANOVA with the between-subjects factor of Dose (0, 0.3, 1.0 and 3.0 mg/kg α-PVP) and within-subjects factor of Time (pre-injection, 30, 60, 120 and 180 min post-injection). In the instance of a significant 2-way interaction, simple effects of Dose at each Time (multivariate analyses) and Time at each Dose (multivariate analyses) were assessed. Significance level for all statistical tests was set to α = 0.05. The 4 × 4 mixed model ANOVA on water consumption on Recovery Nelson et al. Pharmacology, Biochemistry and Behavior 156 (2017) Fig. 3 ). The one-way ANOVA on the total fluid consumed (water + saccharin) during the final two-bottle test revealed no significant differences between groups [F(3, 29) = 1.31, p = 0.290] (data not shown).
Conditioned place preference
A 2 × 4 mixed model ANOVA on percent of time spent on the drugpaired side revealed a main effect of Test [F(1, 29) = 21.708, p = 0.000] such that percent time increased from Pre-test to Post-test. There was no effect of Dose [F(3, 29) = 1.701, p = 0.189] nor a significant interaction between Test and Dose [F(3, 29) = 1.104, p = 0.363]. Due to the lack of a significant interaction, groups were collapsed across dose (all α-PVP treated subjects) and a 2 × 2 mixed model ANOVA was run with the between group factor of Drug (α-PVP and Vehicle) and the within-group factor of Test (Pre-test and Post-test). Although the overall initial interaction was not significant, pairwise comparisons showed that drug-exposed animals (collapsed across dose) significantly increased time spent in the drug-paired chamber from Pretest to Post-test [F(1, 31) = 20.282, p = 0.000] while time spent on the drug-paired side for Group Vehicle did not significantly change [F(1, 31) = 1.645, p = 0.209] (see Fig. 4 ).
Temperature assessment
α-PVP produced dose-dependent increases in temperature. The 4 × 5 mixed model ANOVA on temperature revealed significant effects K.H. Nelson et al. Pharmacology, Biochemistry and Behavior 156 (2017) [48] [49] [50] [51] [52] [53] [54] [55] of 
Discussion
Given that the rewarding effects of α-PVP have recently been described in a variety of preparations (see above), the present study attempted to provide an initial characterization of its aversive effects in rats as indexed by conditioned taste avoidance learning (see Garcia and Ervin, 1968; Riley et al., 2009; Rozin and Kalat, 1971) . Place preference conditioning was concurrently assessed given that the prior demonstration of α-PVP's rewarding effects in the CPP design was with mice and species differences have been reported in this specific assay (see Cunningham et al., 1992; Tzschentke, 2007) . Finally, core body temperature was assessed to extend the prior work of Aarde et al. (2015) who reported a hypothermic effect with this drug (for hyperthermic effects with other bath salts, see Fantegrossi et al., 2013; King et al., 2014; Kiyatkin et al., 2015; Merluzzi et al., 2013; Ross et al., 2012) . As described, α-PVP induced both taste avoidance and place preferences, indicative of its aversive and rewarding effects, respectively. Further, it produced significant increases in body temperature.
In relation to taste avoidance learning, while neither 0.3 nor 1.0 mg/kg α-PVP induced avoidance, significant suppression was evident at the highest dose tested, i.e., 3.0 mg/kg. At this dose, animals reduced consumption of the α-PVP-associated saccharin solution by approximately 40% on the final one-bottle exposure (relative to the initial baseline). These findings are interesting in light of other work with the bath salt MDPV in this design (King et al., 2014 (King et al., , 2015 Merluzzi et al., 2013; Woloshchuk et al., 2016) . For example, Merluzzi et al. (2013) reported that while 1.0 mg/kg MDPV induced relatively weak taste avoidance, 1.8 and 3.2 mg/kg reduced consumption of the drug-paired saccharin solution by approximately 50 and 80%, respectively (see also Woloshchuk et al., 2016; see King et al., 2014 for similar effects in inbred LEW and F344 female rats). The fact that greater avoidance was induced by MDPV (at comparable doses and under similar procedures) suggests that the aversive effects of α-PVP are less potent than MDPV at least as assessed in the taste avoidance design.
As noted above, taste avoidance is induced by a host of other drugs (for reviews, see Gamzu et al., 1985; Hunt and Amit, 1987; Riley, 2011, 2012) , including a variety of psychostimulants such as cocaine (Ferrari et al., 1991; Pomfrey et al., 2015) , MDMA (Cobuzzi et al., 2014) , amphetamine (Verendeev and Riley, 2011) , caffeine (Vishwanath et al., 2011) and nicotine (Pomfrey et al., 2015; Shoaib et al., 2002) . The work with cocaine is most relevant here in that its neurochemical action is similar to that of α-PVP (and MDPV) in terms of blocking the reuptake of the brain amines (see below). Across many behavioral studies examining cocaine-induced taste avoidance (and under training conditions comparable to those described here), suppression of consumption to levels of 40-50% are not evident generally until doses as high as 18 mg/kg are administered (10 mg/kg fails to induce avoidance; Freeman et al., 2005a, b; Serafine et al., 2011 Serafine et al., , 2012 . Suppression to levels of 80 and 90% are not apparent until higher doses (32 and 50 mg/kg) are given. Relative to avoidance induced by α-PVP and MDPV, cocaine appears less potent.
The relative strengths of taste avoidance induced by MDPV, α-PVP and cocaine parallel their relative binding to the brain amine transporters (Aarde et al., 2015; Baumann et al., 2013; Marusich et al., 2014; Simmler et al., 2013) . Specifically, MDPV and α-PVP have stronger affinities for DAT and NET compared to cocaine (MDPV: IC 50 values of 4.1 ± 0.5 nM and 26 ± 8 nM, respectively; α-PVP: IC 50 values of 12.8 ± 1.2 nM and 14.2 ± 1.2 nM, respectively; cocaine: IC 50 values of 211 ± 19 nM and 292 ± 34 nM, respectively) (Baumann et al., 2013; Cameron et al., 2013; Eshleman et al., 2013; Marusich et al., 2014; Simmler et al., 2013) while having relatively less affinity for SERT (IC 50 values of 3349 ± 305 nM, > 10,000 nM and 313 ± 17 nM for MDPV, α-PVP and cocaine, respectively). Previous work on cocaine-induced avoidance (see Freeman et al., 2005a; Hunt et al., 1985; Serafine et al., 2011 Serafine et al., , 2012 ; though see also Gale, 1984) has implicated DA (and to a lesser extent, NE) in its aversive effects. The fact that stronger avoidance is evident with MDPV and α-PVP that have higher binding affinities to the monoamines is consistent with their role in taste avoidance induced by the bath salts.
The fact that α-PVP induces significant taste avoidance is interpreted here as evidence of its aversive effects in that such avoidance may be biologically relevant given that foods are often sources of poisons and toxins and such avoidance (and learning) is highly adaptive (for a discussion, see Rozin and Kalat, 1971 ; for a recent review, see Lin et al., 2016) . There are other interpretations of such avoidance, however. One possible interpretation of the suppression of consumption is that it reflects less an association of the taste with the aversive effects of α-PVP than some unconditioned suppressive effects that the drug may have on consumption in general. Although possible, the fact that general fluid consumption on recovery days (immediately after each conditioning trial) was not suppressed suggests there was no general suppression of fluid consumption induced by the drug. As noted, with repeated conditioning for the high dose group, water consumption eventually increased. This effect, however, was not evident until saccharin consumption on conditioning trials was significantly suppressed and likely reflects compensatory intake. Further, fluid consumption on the two-bottle test in which both the drug-paired saccharin solution and water were concurrently presented revealed that only saccharin consumption was suppressed. Total fluid consumption on this test was the same for all groups (including controls).
Again, we are arguing that the suppressed saccharin consumption reflects the aversive effects of α-PVP. It is important to note that while such suppression is generally thought to reflect such effects, Grigson (1997) has argued that taste avoidance under some conditions is a K.H. Nelson et al. Pharmacology, Biochemistry and Behavior 156 (2017) 48-55 function of the rewarding effects of the drug. According to this perspective, the taste paired with the drug (while rewarding) pales in comparison to the drug itself (in this case α-PVP). This anticipatory contrast results in the reduction of intake of the less preferred drugpaired taste. For this position, the drug's rewarding effects induce the avoidance and these two effects should be directly related in specific assessments (see Riley, 2011, 2012 ; see also Riley et al., 2009 ). Interestingly, a number of manipulations that affect taste avoidance learning (and the presumed aversive effects of the drug) have no impact on the drug's rewarding properties (and vice versa). Further, manipulations that increase the drug's rewarding effects have been reported to decrease its ability to induce a taste avoidance (and its presumed aversive effects). Such dissociations have been shown with drug pre-exposure, electrolytic lesions, strain and age comparisons and various other parametric variations (for a discussion, see Riley, 2011, 2012 ; see also Huang and Hsaio, 2008; Wang et al., 2010) . Although the focus of the present study was primarily to assess the aversive effects of α-PVP, its rewarding effects were concurrently evaluated in the place conditioning design. The fact that α-PVP induced place preferences parallels the work by Gatch et al. (2015) who reported place preference conditioning in mice at 0.3-10 mg/kg, a dose range that encompassed that used here. One major difference between the two assessments was the fact that preferences were not dose-dependent with rats but dose-dependent in mice. Given that species differences in place conditioning have been reported (for ethanol, see Cunningham et al., 1993 ; for cannabinoids, see Flax et al., 2015; Zimmer et al., 2001) , it is certainly possible that the presence or absence of a dose-dependent effect could be a function of the specific species assessed. Although it is clear that in both rats and mice α-PVP appears to have rewarding effects, it is important to note that the specific nature of these effects is open to various interpretations. In the present assessment, animals were injected with α-PVP and placed on their non-preferred side (vehicle injections preceded placement on their preferred side). A production of a place preference in a biased procedure may reflect factors other than reward, such as habituation to the aversive effects of the drug (see Bardo and Bevins, 2000) or some negatively reinforcing effects of the drug such as anxiety reduction (for a review, see Tzschentke, 1998 Tzschentke, , 2007 . Although this latter possibility is unlikely with compounds such as α-PVP which are anxiogenic (Baumann et al., 2013; Ross et al., 2012; Valente et al., 2014; Xu et al., 2016) , it remains unknown what specific subjective effects of the drug support place preference conditioning.
In an effort to extend the work of Aarde et al. (2015) with α-PVPinduced changes in temperature, in the current study rats were injected with α-PVP (IP) and body temperature was recorded for 3 h (for other reports of hyperthermic effects induced by other bath salts, see Fantegrossi et al., 2013; Gannon et al., 2016; King et al., 2014; Kiyatkin et al., 2015; Merluzzi et al., 2013) . Relative to the control group, all three groups injected with α-PVP displayed significant increases in temperature. In addition, the effects on temperature were dose-and time-dependent. For example, significant effects on temperature were seen within 30 min post injection at only the high dose of α-PVP (Group 3.0), while at 60 and 90 min all α-PVP injected groups displayed significant hyperthermia relative to controls. The duration of the effects also varied with dose as the low dose group (Group 0.3) was no longer different from controls by 180 min. When examined over the sampling period only Groups 1.0 and 3.0 increased temperature relative to their own baseline (this was evident at all intervals for Group 3.0 and only at the 90 and 180 periods for Group 1.0), while there were no changes in baseline activity for Groups Vehicle or 0.3. Although these results are not consistent with the hypothermia reported by Aarde et al., it is important to note that the doses of α-PVP used in the present assessment were lower than those used by his group, and it is certainly possible that had higher doses been used hypothermic effects would have been seen (Pechlivanova et al., 2010) .
Although the temperature assessment was made primarily to extend the limited work on temperature changes with α-PVP, this analysis also allowed for an initial investigation of any possible relationship between changes in temperature and taste avoidance as has been reported in other assessments with other compounds (see Cunningham et al., 1988 Cunningham et al., , 1992 Ionescu and Burešová, 1977) . While no direct statistical comparisons could be made due to the randomization of dose groups between assessments, changes in temperature had no obvious relationship with the ability of α-PVP to induce taste avoidance considering that all doses induced hyperthermia but only the highest dose (3.0 mg/kg) induced significant taste avoidance. These findings parallel our earlier work with MDPV, indicating that hyperthermia is unlikely the basis for the acquired avoidance with either α-PVP or MDPV (see King et al., 2014 King et al., , 2015 Merluzzi et al., 2013) .
While it is clear that α-PVP, like MDPV and other drugs of abuse, has both rewarding and aversive effects, the specific factors influencing these effects remain unknown. For each of these affective properties, a host of subject (sex, age, strain, species) and experiential (dose of drug, drug history, route of administration, drug frequency) factors are known to impact their display (Cunningham et al., 2008; Freeman and Riley, 2009; Riley et al., 2009) . Given that the balance of these affective properties is thought to mediate use and abuse potential, it will be important to examine how these factors impact the rewarding and aversive effects of α-PVP and how the relative balance of these effects influence α-PVP intake.
Role of funding source
